Event Details

**ALL SHOWCASE SLOTS TAKEN**


Further to the sell-out success of our annual BioSeed pitching event, we are pleased to deliver our 3rd BioSeed Lunchtime Express - a bite-size lunch-hour version, that is a perfect platform for companies who would like to trial a fast-paced pitch in a slightly less formal setting.


BioSeed Lunchtime Express will take place on Thursday 30 September from 12.00 โ€“ 13.00 and will feature 4 x 7-minute live presentations from life sciences companies across all therapy areas, seeking Seed or Series A funding up to ยฃ2.5million.

Attendance at the event is open to fellow R&D companies and active Life Science investors.


Event Programme

12:00 Welcome by OBN & Event Host

12:05 Company Showcase 1: VeinSense​

12:15 Company Showcase 2: OncoNex Therapeutics

12:25 Company Showcase 3: FluoretiQ​

12:35 Company Showcase 4: Neuro-Bio​

12:45 Final comments

13:00 Event Close


Who Should Attend


Early-Stage Companies Seeking Seed or Series A Investment


Digital showcase presentation slots are available for start-up and early-stage Life Sciences companies who are actively seeking Seed or Series A funding of up to ยฃ2.5 million.

Active Life Science Investors


Investor tickets are available for active investors with a genuine interest in funding early-stage Life Science companies.


Terms and Conditions of OBN Events

Agenda

12:00 - 12:15
Company Showcase 1 - VeinSense
VeinSense concentrates on the treatment of venous leg ulcers (VLUs); affecting >500,000 in the UK, ~3million (USA) and ~4million (Europe), currently costing the UKโ€™s NHS >ยฃ3billion p.a. to m...
VeinSense concentrates on the treatment of venous leg ulcers (VLUs); affecting >500,000 in the UK, ~3million (USA) and ~4million (Europe), currently costing the UK’s NHS >£3billion p.a. to manage. For 40 years, with little innovation in VLU treatment, both healing and concordance rates remain depressingly low.
VeinSense’s vision is to improve healing rates, minimise patient discomfort and dramatically reduce healthcare costs by creating an innovation-driven, patient-centric, successful business.
Key, is to simplify the accurate and reproducible application of graduated compression, to be achieved using world-first, multi-patented, Graducheck® technology – a multi-point, pressure sensor strip that allows patient-tailored, graduated compression profiles to be achieved with either bandage systems, wraps or socks and applied by HCA’s/’carers’ in addition to more experienced clinicians.
Remote monitoring will give unique insight in to the variability of compression levels 24/7, with data gathered prompting ‘as needed-only’ treatments that should enhance management and improve healing rates even further.
view more
12:15 - 12:25
Company Showcase 2 - OncoNex Therapeutics
OncoNex focus isย ๏ปฟT cell exhaustion reversion and combination therapies for anti-PD1 refractory cancer patients.OncoNex proposes tackling solid tumours with more integrated and novel treatme...
OncoNex focus is ๏ปฟT cell exhaustion reversion and combination therapies for anti-PD1 refractory cancer patients.
OncoNex proposes tackling solid tumours with more integrated and novel treatment solutions, notably by implementing concepts of hallmarks of cancer, patient population stratification, and T cell exhaustion reversion using small molecules in combination therapies to leverage multiple non-redundant mechanisms of action for achieving tumour debulking and relapse prevention.
view more
12:25 - 12:35
Company Showcase 3 - FluoretiQ
FluoretiQ have developed NANOPLEXโ„ข- a rapid diagnostic platform that identifies bacterial pathogens in 15 minutes. This is a ground breaking technology that enables clinicians to confidently...
FluoretiQ have developed NANOPLEX™- a rapid diagnostic platform that identifies bacterial pathogens in 15 minutes. This is a ground breaking technology that enables clinicians to confidently use antibiotics at the very start of patient treatment.
NANOPLEX™ uses a library of glycan-based probes that mimic the adhesion phase of infection. Using low-cost imaging techniques we can identify the bacterial species and determine whether a clinically significant concentration is present.
view more
12:35 - 12:45
Company Showcase 4 - Neuro Bio
Neuro-Bio has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE.ย  T14 is neurotoxic in the adult brain and published data shows it to be a potentia...
Neuro-Bio has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE.  T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of nerodegeneration.  This new distinct mechanism is being exploited by Neuro-Bio to discover first-in-class drugs to treat Alzheimer's disease and to develop a biomarker as a companion diagnostic.
view more

Community

Discover and connect with other attendees.

PT